AGOMELATINE IN THE TREATMENT OF ANXIETY AND DEPRESSIVE DISORDERS IN PATIENTS WITH ISCHEMIC HEART DISEASE

• Published in: Rat͡s︡ionalʹnai͡a︡ farmakoterapii͡a︡ v kardiologii Vol. 13; no. 1; pp. 116 - 123
• Main Authors: Shimohina, N. Yu, Petrova, M. M., Savchenko, A. A., Chernyaeva, M. S.
• Format: Journal Article
• Language: English
• Published: Столичная издательская компания 01-01-2017
• Subjects: agomelatine; antidepressants; anxiety; depression; ischemic heart disease
• ISSN: 1819-6446; 2225-3653
• DOI: 10.20996/1819-6446-2017-13-1-116-123

According to the World Health Organization, anxiety and depressive disorders will be the second  leading cause of disability by 2020. The review is devoted to the modern concepts of the pathophysiology of depression in patients with ischemic heart  disease (IHD) and to the possibilities of antidepressant therapy. The paper presents analysis of international and domestic researches devoted to efficiency and safety of agomelatine in patients both  with chronic IHD and with unstable angina and acute  myocardial infarction. The review also discusses different points of view, indicating the need for further  studies to evaluate the short and long term effects of antidepressants in patients with IHD in combination with anxiety and depressive disorders.